InvestorWire NewsRoom

Article

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Pioneering Efforts as Studies, Research Show Psilocybin’s Potential in Treating AUD
August 31, 2022

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Pioneering Efforts as Studies, Research Show Psilocybin’s Potential in Treating AUD

  • A new study shows promise in treating alcohol addiction with psychedelic mushroom compound, psilocybin
  • These results align with efforts and expectations of Cybin, a leading ethical biopharmaceutical company championing psilocybin
  • After receiving FDA approval, the company is moving forward with a first-in-human clinical trial evaluating CYB003

A new study published in JAMA Psychiatry offers hope for those struggling with alcoholism (https://ibn.fm/jV5o9), showing promise in treating alcohol addiction with the psychedelic compound psilocybin. This news aligns with initiatives of Cybin (NEO: CYBN) (NYSE American: CYBN), a leading ethical biopharmaceutical company, which has a drug in development, CYB003, for the treatment of alcohol use disorder (“AUD”) and major depressive disorder (“MDD”) (https://ibn.fm/5IPD1).

In addition to reporting three million deaths annually attributed to alcohol use (5.3% of all deaths), the World Health Organization (“WHO”) states that the harmful use of alcohol is a causal factor in more than 200 diseases and injury conditions and that, overall, 5.1% of the global burden of disease and injury is attributable to alcohol (https://ibn.fm/ytu6c). These statistics make the JAMA-published study even more significant.

The study, conducted by the Department of Psychiatry at New York University’s (“NYU”) Langone Center for Psychedelic Medicine, discovered that providing two doses of psilocybin and psychotherapy reduced heavy drinking by 83% within eight months.

“In this double-blind, randomized clinical trial with 93 participants, the percentage of heavy drinking days during 32 weeks of follow-up was significantly lower in the psilocybin group than in the placebo group, containing the antihistamine diphenhydramine,” the article stated.

By contrast, those who received the antihistamine placebo only reduced their drinking by 51%. All participants received up to 12 psychotherapy sessions before and after the psilocybin treatments.

The study concluded that administering psilocybin in combination with psychotherapy “produced robust decreases in the percentage of heavy drinking days over and above those produced by active placebo and psychotherapy. These results provide support for further study of psilocybin-assisted treatment for Alcohol Use Disorder (‘AUD’).”

These results align with the efforts and expectations of Cybin, which is creating Psychedelics to Therapeutics(TM). The company is making significant headway with its flagship deuterated psilocybin analog, CYB003. CYB003 has the potential to effectively treat AUD and MDD. The substance is designed to achieve less variability in plasma levels, faster onset of action, shorter duration of effect, and potentially better tolerability than oral psilocybin for a better patient outcome overall.

Earlier this summer, Cybin received a “may proceed” letter and Investigational New Drug Application (“IND”) clearance from the U.S. Food and Drug Administration (“FDA”) for its Phase 1/2a first-in-human clinical trial evaluating CYB003 (https://ibn.fm/OQsmP). This milestone achievement marks the industry’s first-ever novel psilocybin analog to enter clinical development; the company has started recruiting patients and expects to provide an interim pharmacokinetic and safety readout later this year.

“We are extremely pleased to advance CYB003 into clinical development so quickly,” said Cybin CEO Doug Drysdale. “Our team has worked diligently to achieve this major regulatory milestone, and we look forward to collaborating with Clinilabs, our drug development partner, to accelerate this program. This Phase 1/2a trial represents the first time that a psilocybin analog will be evaluated in humans for the treatment of MDD and is the key next step toward our ultimate goal of providing a new and effective treatment for people suffering from mental health conditions.”

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).